Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Brotman Baty Institute, |
RCV001077329 | SCV001243243 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro | ||
KCCC/NGS Laboratory, |
RCV001077329 | SCV003927200 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-05-05 | no assertion criteria provided | clinical testing | The BRCA1 mutation detected in this specimen (c.5406+2T>G) show sequence change affects a splice site in intron area after exon 22 of the BRCA1 gene . It is expected to disrupt RNA splicing and likely results in an absent or disrupts protein product . This variant is previously reported (PMID: 25329591) associated with breast cancer. ClinVar has an entry for this variant (ID:868431). This variant is also known as c.5469+2T>G. Donor and acceptor splice site variants typically lead to disrupt protein and loss of function. A functional study (PMID: 25329591) shows this variant results in loss of function. The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5406+2T>G, a CANONICAL SPLICE variant, produced a function score of -1.44, corresponding to a functional classification of LOSS_OF_FUNCTION. This variant is not found in gnomAD genomes. In-silico predictions show Pathogenic computational verdict based on 6 pathogenic predictions from BayesDel_addAF, DANN, EIGEN, FATHMM-MKL, MutationTaster and scSNV-Splicing vs no benign predictions. Therefore, this variant has been classified as Likely pathogenic. |